Cargando…

Subpopulations of High-Density Lipoprotein: Friends or Foes in Cardiovascular Disease Risk in Chronic Kidney Disease?

Dyslipidemia is a major traditional risk factor for cardiovascular disease (CVD) in chronic kidney disease (CKD) patients, although the altered lipid profile does not explain the number and severity of CVD events. High-density lipoprotein (HDL) is a heterogeneous (size, composition, and functionalit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Coimbra, Susana, Reis, Flávio, Valente, Maria João, Rocha, Susana, Catarino, Cristina, Rocha-Pereira, Petronila, Sameiro-Faria, Maria, Bronze-da-Rocha, Elsa, Belo, Luís, Santos-Silva, Alice
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8157071/ https://www.ncbi.nlm.nih.gov/pubmed/34065648 http://dx.doi.org/10.3390/biomedicines9050554

Ejemplares similares

The Protective Role of Adiponectin for Lipoproteins in End-Stage Renal Disease Patients: Relationship with Diabetes and Body Mass Index
por: Coimbra, Susana, et al.
Publicado: (2019)

Long Pentraxin 3 as a Broader Biomarker for Multiple Risk Factors in End-Stage Renal Disease: Association with All-Cause Mortality
por: Valente, Maria João, et al.
Publicado: (2019)

Interleukin 6 (rs1800795) and pentraxin 3 (rs2305619) polymorphisms-association with inflammation and all-cause mortality in end-stage-renal disease patients on dialysis
por: Rocha, Susana, et al.
Publicado: (2021)

Cell-free DNA as a marker for the outcome of end-stage renal disease patients on haemodialysis
por: Coimbra, Susana, et al.
Publicado: (2020)

Hepcidin and diabetes are independently related with soluble transferrin receptor levels in chronic dialysis patients
por: Belo, Luís, et al.
Publicado: (2019)

New Insights into Adiponectin and Leptin Roles in Chronic Kidney Disease
por: Coimbra, Susana, et al.
Publicado: (2022)

The Association of Leptin with Left Ventricular Hypertrophy in End-Stage Kidney Disease Patients on Dialysis
por: Coimbra, Susana, et al.
Publicado: (2023)

Potential Cardiovascular Risk Protection of Bilirubin in End-Stage Renal Disease Patients under Hemodialysis
por: do Sameiro-Faria, Maria, et al.
Publicado: (2014)

Resistance to Recombinant Human Erythropoietin Therapy in a Rat Model of Chronic Kidney Disease Associated Anemia
por: Garrido, Patrícia, et al.
Publicado: (2015)

Risk Factors for Mortality in Hemodialysis Patients: Two-Year Follow-Up Study
por: do Sameiro-Faria, Maria, et al.
Publicado: (2013)

Bilirubin is independently associated with oxidized LDL levels in young obese patients
por: Nascimento, Henrique, et al.
Publicado: (2015)

Iron-Hepcidin Dysmetabolism, Anemia and Renal Hypoxia, Inflammation and Fibrosis in the Remnant Kidney Rat Model
por: Garrido, Patrícia, et al.
Publicado: (2015)

Inflammatory Disturbances in Preeclampsia: Relationship between Maternal and Umbilical Cord Blood
por: Catarino, Cristina, et al.
Publicado: (2012)

Renin angiotensin system in liver diseases: Friend or foe?
por: Simões e Silva, Ana Cristina, et al.
Publicado: (2017)

Body Fat Percentage Is a Major Determinant of Total Bilirubin Independently of UGT1A1*28 Polymorphism in Young Obese
por: Belo, Luís, et al.
Publicado: (2014)

Long-Distance Counter Calling in Maned Wolves: Friends or Foes?
por: Ferreira, Luane S., et al.
Publicado: (2022)

MicroRNAs Expression Profiles in Cardiovascular Diseases
por: Bronze-da-Rocha, Elsa
Publicado: (2014)

Markers of Increased Cardiovascular Risk in Postmenopausal Women: Focus on Oxidized-LDL and HDL Subpopulations
por: Mascarenhas-Melo, Filipa, et al.
Publicado: (2013)

Targeting Macrophages: Friends or Foes in Disease?
por: Ardura, Juan A., et al.
Publicado: (2019)

ZEB Proteins in Leukemia: Friends, Foes, or Friendly Foes?
por: Soen, Bieke, et al.
Publicado: (2018)

Friend and Foe
Publicado: (1890)

Neutrophil Elastase Inhibitors and Chronic Kidney Disease
por: Bronze-da-Rocha, Elsa, et al.
Publicado: (2018)

Implication of Low HDL-c Levels in Patients with Average LDL-c Levels: A Focus on Oxidized LDL, Large HDL Subpopulation, and Adiponectin
por: Mascarenhas-Melo, Filipa, et al.
Publicado: (2013)

microRNAs in mycobacterial disease: friend or foe?
por: Mehta, Manali D., et al.
Publicado: (2014)

Tim-4 in Health and Disease: Friend or Foe?
por: Liu, Wen, et al.
Publicado: (2020)

S-glutathionylation, friend or foe in cardiovascular health and disease
por: Rashdan, N.A., et al.
Publicado: (2020)

The oral microbiome in autoimmune diseases: friend or foe?
por: Huang, Xiaoyan, et al.
Publicado: (2023)

Oxygen for the Newborn: Friend or Foe?
por: Perrone, Serafina, et al.
Publicado: (2023)

Phytoestrogens. Friends or foes?
por: Barrett, J
Publicado: (1996)

Polypill—Friend or Foe?
por: Rishi, Rakesh Kumar
Publicado: (2011)

Antioxidants - friend or foe?
por: Meffert, Hans
Publicado: (2008)

Inflammation: Friend and Foe
por: Kjekshus, John
Publicado: (2015)

Leukocytes: friend or foe
por: Bellingan, G
Publicado: (2000)

Viruses: Friends or foes
por: Michán, Carmen, et al.
Publicado: (2021)

Sphingolipids: Friends or Foes?
por: Hayashi, Hiroshi
Publicado: (2022)

Gabapentin—Friend or foe?
por: Russo, Marc, et al.
Publicado: (2022)

Nonparametric statistical tests: friend or foe?
por: Politi, María Teresa, et al.
Publicado: (2021)

Growth factors in lung development and disease: friends or foe?
por: Desai, Tushar J, et al.
Publicado: (2002)

Phosphoinositide 3-kinase: friend and foe in cardiovascular disease
por: Ghigo, Alessandra, et al.
Publicado: (2015)

Glucose Transporters in Diabetic Kidney Disease—Friends or Foes?
por: Wasik, Anita A., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_oi68du641nm4u88qh8s1lat705